Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Bundles Legacy Drugs Into Separate Portfolio In Housekeeping Move

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.

You may also be interested in...



GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen

Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.

Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J, GSK (Part 3)

After Abbott/AbbVie split, emerging markets represent 40% of Abbott’s sales compared to 15% of AbbVie sales. Abbott, J&J and GSK report dismal sales in Europe, noting that EMs remain a bright spot.

GSK Reviews Options For European Business, Adopts New Manufacturing Processes

GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel